Skip to main content
TipRanks
Go Ultimate75% OFF

Bactiguard Holding AB (BACTI.B) AI Stock Analysis

0 Followers
SE:BACTI.B

Bactiguard Holding AB

(Nasdaq OMX AB:BACTI.B)

Select Model
Rating:47Neutral
Price Target:SEK 15.50â–²(4.38% Upside)
Action:upgraded
Date:10/24/26

Bactiguard scores below average, weighed down primarily by fundamentals that remain in transition: five years of flat revenue, still-negative operating income and a negative P/E of -64.6 show the business has yet to prove it can grow or sustain profitability, even as EBITDA has swung from a SEK -90m loss in 2023 to about SEK +49m TTM and free cash flow has turned positive. The balance sheet is a genuine strength — leverage reduced to roughly 0.52 debt-to-equity with equity funding about 60% of assets — but the capital base has shrunk materially through accumulated losses, leaving limited room for further missteps. Technicals add no support, with the price below all major moving averages and a negative MACD indicating a persistent downward drift, while the absence of a dividend means no income cushion. The investment case rests on management converting recent cost and cash-flow gains into sustained revenue growth; until that is evident, execution risk keeps the score muted. Weights applied: Financial Performance 50%, Technical Analysis 30%, Valuation 20%, with earnings call and corporate events excluded for lack of data and their weight redistributed.

Positive Factors
Improving Cash GenerationThe return to positive operating and free cash flow strengthens internal funding capacity and reduces reliance on external financing. If maintained, better cash conversion can support product development, partner implementation, and regulatory activity while providing greater resilience through normal business fluctuations.
Negative Factors
Unproven ProfitabilityDespite substantial improvement from earlier losses, the company has not yet demonstrated durable operating profitability or positive shareholder returns. Continued losses could limit internally funded growth, weaken confidence in the business model, and make results more sensitive to execution and adoption timing.

Bactiguard Holding AB (BACTI.B) vs. iShares MSCI Sweden ETF (EWD)

-30%-20%-10%0%10%20%30%SE:BACTI.B-17.27%EWD+8.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 520.40M
Dividend Yield
―
Average Volume (3M)
6,890
Price to Earnings (P/E)
82.5
Beta (1Y)
0.30
Revenue Growth
-0.51%
EPS Growth
―
Country
Sweden
Employees
166
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Bactiguard Holding AB Business Overview & Revenue Model

Company Description

Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HAIs)...

How the Company Makes Money

Bactiguard makes money primarily through (1) licensing its infection-prevention coating technology to medical device manufacturers and (2) selling coated medical devices in certain product categories/markets, depending on how products are commerciali...

Bactiguard Holding AB Financial Statement Overview

Summary

A turnaround in progress, but not yet complete. The income statement is the weakest link (score 41): revenue has been flat-to-choppy for five years at roughly SEK 170–244m (about SEK 215m TTM, down 11% in 2025 after +19% in 2024), EBIT remains marginally negative at about SEK -2m TTM, and the reported gross margin step-down from the 77–86% range to about 42% clouds visibility on unit economics. The balance sheet is the strongest pillar (score 60): debt has been cut from about SEK 248m in 2021 to SEK 154m, debt-to-equity has improved to roughly 0.52, and equity of about SEK 313m funds around 60% of assets — though the equity base has shrunk sharply from SEK 541m in 2021 on accumulated losses. Cash flow (score 55) has turned positive with about SEK 30m operating and SEK 28m free cash flow TTM on light capex, but it has flipped between positive and negative in four of the last five years, so consistency is unproven. Net: real cost and cash discipline progress, offset by absent revenue growth and lingering execution risk.

Income Statement

41Neutral

Balance Sheet

60Neutral

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue214.73M215.92M243.68M203.99M223.56M169.49M
Gross Profit145.46M184.65M207.71M139.98M180.14M130.80M
EBITDA48.72M45.15M24.99M-89.98M-543.00K-5.94M
Net Income6.02M-7.84M-29.82M-138.38M-52.88M-58.77M
Balance Sheet
Total Assets524.24M545.06M655.91M662.17M807.70M849.29M
Cash, Cash Equivalents and Short-Term Investments55.05M44.26M116.73M123.22M197.73M217.59M
Total Debt153.75M162.92M227.77M233.10M238.70M247.96M
Total Liabilities210.91M230.13M327.57M309.00M311.99M307.84M
Stockholders Equity313.33M314.93M328.34M353.18M495.71M541.45M
Cash Flow
Free Cash Flow27.59M-7.21M10.21M-60.94M-7.86M-38.00K
Operating Cash Flow30.38M-1.49M24.99M-52.33M3.06M7.26M
Investing Cash Flow-2.79M-5.72M-14.78M-8.61M-10.92M-7.29M
Financing Cash Flow-13.31M-62.74M-21.20M-11.84M-13.89M205.83M

Bactiguard Holding AB Technical Analysis

Technical Analysis SentimentNegative
Last Price14.85

Price Trends

50DMA15.63Negative
100DMA15.77Negative
200DMA16.10Negative

Market Momentum

MACD-0.16Positive
RSI43.82Neutral
STOCH61.03Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BACTI.B, the sentiment is Negative. The current price of 14.85 is below the 20-day moving average (MA) of 15.51, below the 50-day MA of 15.63, and below the 200-day MA of 16.10, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 43.82 is Neutral, neither overbought nor oversold. The STOCH value of 61.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BACTI.B.

Bactiguard Holding AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:BACTI.B against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:GETI.BSE:GETI.B67NeutralSEK 75.39B26.649.13%1.72%-3.90%37.73%
SE:SEZISE:SEZI55NeutralSEK 510.16M-5.23-35.44%―18.56%28.11%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:BACTI.BSE:BACTI.B47NeutralSEK 520.40M82.501.93%―-0.51%―
SE:INTEG.BSE:INTEG.B45NeutralSEK 238.78M-5.66-20.71%―1.43%4.98%
SE:OSSDSE:OSSD45NeutralSEK 329.67M-6.59――-11.89%-11.85%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%SE:BACTI.BSE:GETI.BSE:SEZISE:INTEG.BSE:PROSE:OSSDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:BACTI.B and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:BACTI.BBactiguard Holding AB14.85-1.50-9.17%
SE:GETI.BGetinge AB (UK)276.8071.2534.66%
SE:SEZISenzime AB3.25-1.81-35.87%
SE:INTEG.BIntegrum AB Class B8.14-0.79-8.85%
SE:PROPromimic AB9.00-8.05-47.21%
SE:OSSDOssDsign AB2.98-7.42-71.35%

Bactiguard Holding AB Corporate Events

Bactiguard’s Partnership-Driven Growth Delivers Strong Q3 Turnaround

Oct 22, 2026

Bactiguard Holding AB reported a strong third quarter 2026, with total revenue rising 20.6% to SEK 58.4 million and net sales up 21.2% to SEK 55.1 million, driven mainly by its partnership model. Operating profit swung to SEK 6.8 million from a loss...

Bactiguard Sets Date for Q3 2026 Report and Investor Audiocast

Oct 16, 2026

Bactiguard Holding AB will publish its interim report for the third quarter of 2026 on 22 October at 07:00 CEST. The MedTech firm is organizing an audiocast and conference call the same day at 11:00 CEST, where CEO Christine Lind and CFO Patrick Bach...

Bactiguard Data Highlight Durable, Low-Silver Coating for Orthopedic Implants

Sep 17, 2026

Bactiguard has unveiled new data on its noble metal coating technology, reinforcing its distinct and durable performance on orthopedic implants. Presented at major international arthroplasty and infection conferences, the findings position the compan...

Bactiguard Adjusts Share Structure to Support 2026 Incentive Plan

Jul 31, 2026

Bactiguard Holding AB, a Stockholm-based MedTech firm listed on Nasdaq Stockholm’s Small Cap segment, develops noble metal coating technologies that prevent infections on medical devices and offers wound care products across orthopedics, cardiology,...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 24, 2026